

## ASX Announcement

30 September 2019

### Explanatory Note to the 2019 Annual Report

Bioxyne Limited (ASX:BXN) provides the following explanatory note to a difference between the unaudited preliminary final result released on 28 August 2019 (**Preliminary Financials**) and the audited annual report released to the market on 30 September 2019 (**Annual Report**).

The Preliminary Financials disclosed a loss of \$1,365,882. The Annual Report disclosed a loss of \$1,265,882.

The difference relates to the accounting for share based payments performance rights. Certain performance hurdles for the 2019 financial year were not achieved. As a consequence 20,000,000 performance rights issued in 2017 will lapse and 4,500,000 performance rights issued in 2018 will lapse. A reconciliation of the difference between the preliminary final report and the annual report is as follows:

	Appendix 4E	Annual Report
Share based payment expense	(119,500)	(19,500)
Net loss after tax	(1,365,882)	(1,265,882)
Accumulated losses	(59,371,768)	(59,196,768)
Reserves	283,467	108,467

For further information, please contact:

Guy Robertson  
Company Secretary  
+ 61 2 9078 8180